These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 15372824)

  • 21. Prevalence of hypoglycemia among a sample of sulfonylurea-treated patients with Type 2 diabetes mellitus in Argentina: The real-life effectiveness and care patterns of diabetes management (RECAP-DM) study.
    Gonzalez C; Monti C; Pinzon A; Monsanto H; Ejzykowicz F;
    Endocrinol Diabetes Nutr (Engl Ed); 2018 Dec; 65(10):592-602. PubMed ID: 30076124
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Insulin in type 2 diabetes: a useful alternative despite limited assessment based on surrogate endpoints.
    Prescrire Int; 2005 Oct; 14(79):187-93. PubMed ID: 16285076
    [TBL] [Abstract][Full Text] [Related]  

  • 23. United Kingdom Prospective Diabetes Study 24: a 6-year, randomized, controlled trial comparing sulfonylurea, insulin, and metformin therapy in patients with newly diagnosed type 2 diabetes that could not be controlled with diet therapy. United Kingdom Prospective Diabetes Study Group.
    Ann Intern Med; 1998 Feb; 128(3):165-75. PubMed ID: 9454524
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Discrepancies among consensus documents, guidelines, clinical practice and the legal framework for the treatment of type 2 diabetes mellitus patients.
    del Pozo-Fernández C; Pardo-Ruiz C; Sánchez-Botella C; Blanes-Castañer V; López-Menchero R; Gisbert-Sellés C; Sánchez-Jodar C; Alvarez-Avellán L
    Nefrologia; 2012 May; 32(3):367-73. PubMed ID: 22592422
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effectiveness and Safety of Adding Basal Insulin Glargine in Patients with Type 2 Diabetes Mellitus Exhibiting Inadequate Response to Metformin and DPP-4 Inhibitors with or without Sulfonylurea.
    Kang YM; Jung CH; Lee SH; Kim SW; Song KH; Kim SG; Kim JH; Cho YM; Park TS; Ku BJ; Koh G; Kim DM; Lee BW; Park JY
    Diabetes Metab J; 2019 Aug; 43(4):432-446. PubMed ID: 31237133
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A Prospective Study of the Clinical and Demographic Profile of Type 2 Diabetes Mellitus Patients Receiving Antidiabetic Drug Combinations.
    Gadgade A; Kudgi AS; Kamath A; Kamath P; Adhikari P; Revappala NS; Hadigal S; Natarajan S; Shenoy N; Chowta MN
    Curr Diabetes Rev; 2020; 16(5):503-508. PubMed ID: 31250763
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Triple therapy in type 2 diabetes: insulin glargine or rosiglitazone added to combination therapy of sulfonylurea plus metformin in insulin-naïve patients: response to Rosenstock et al.
    Hamid Z; Simmons DL
    Diabetes Care; 2006 Oct; 29(10):2331; author reply 2332. PubMed ID: 17003324
    [No Abstract]   [Full Text] [Related]  

  • 28. Addition of neutral protamine lispro insulin or insulin glargine to oral type 2 diabetes regimens for patients with suboptimal glycemic control: a randomized trial.
    Esposito K; Ciotola M; Maiorino MI; Gualdiero R; Schisano B; Ceriello A; Beneduce F; Feola G; Giugliano D
    Ann Intern Med; 2008 Oct; 149(8):531-9. PubMed ID: 18936501
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Addition of pioglitazone or bedtime insulin to maximal doses of sulfonylurea and metformin in type 2 diabetes patients with poor glucose control: a prospective, randomized trial.
    Aljabri K; Kozak SE; Thompson DM
    Am J Med; 2004 Feb; 116(4):230-5. PubMed ID: 14969650
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [New rank order of antidiabetic drugs. Using glitazone before sulfonylurea drugs? (interview by Dr. Dirk Einecke)].
    Jacob S
    MMW Fortschr Med; 2007 Jan; 149(1-2):14. PubMed ID: 17632857
    [No Abstract]   [Full Text] [Related]  

  • 31. Long-term effects of glimepiride or rosiglitazone in combination with metformin on blood pressure control in type 2 diabetic patients affected by the metabolic syndrome: a 12-month, double-blind, randomized clinical trial.
    Derosa G; Cicero AF; Gaddi AV; Ciccarelli L; Piccinni MN; Salvadeo S; Pricolo F; Fogari E; Ghelfi M; Ferrari I; Fogari R
    Clin Ther; 2005 Sep; 27(9):1383-91. PubMed ID: 16291411
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Improved blood sugar control plus weight loss].
    Göke B
    MMW Fortschr Med; 2006 Aug; 148(33-34):51. PubMed ID: 16981389
    [No Abstract]   [Full Text] [Related]  

  • 33. Combined therapy with insulin plus oral agents: is there any advantage? An argument in favor.
    Riddle MC
    Diabetes Care; 2008 Feb; 31 Suppl 2():S125-30. PubMed ID: 18227472
    [No Abstract]   [Full Text] [Related]  

  • 34. Risk of hypoglycemia following intensification of metformin treatment with insulin versus sulfonylurea.
    Roumie CL; Min JY; Greevy RA; Grijalva CG; Hung AM; Liu X; Elasy T; Griffin MR
    CMAJ; 2016 Apr; 188(6):E104-E112. PubMed ID: 26811361
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [SGLT-2-inhibitor dapagliflozin: new treatment approach for diabetes type 2--new achievements, but also new questions!].
    Nauck M; Del Prato S
    Dtsch Med Wochenschr; 2013 Apr; 138 Suppl 1():S4-5. PubMed ID: 23529569
    [No Abstract]   [Full Text] [Related]  

  • 36. Efficacy of combined treatments in NIDDM patients with secondary failure to sulphonylureas. Is it predictable?
    Trischitta V; Italia S; Raimondo M; Guardabasso V; Licciardello C; Runello F; Mazzarino S; Sangiorgi L; Anello M; Vigneri R
    J Endocrinol Invest; 1998 Dec; 21(11):744-7. PubMed ID: 9972673
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Association between intensification of metformin treatment with insulin vs sulfonylureas and cardiovascular events and all-cause mortality among patients with diabetes.
    Roumie CL; Greevy RA; Grijalva CG; Hung AM; Liu X; Murff HJ; Elasy TA; Griffin MR
    JAMA; 2014 Jun; 311(22):2288-96. PubMed ID: 24915260
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Evaluation, efficacy and tolerability of GlucoNovax tablet in type 2 diabetic patients.
    Ali Z; Daniyal M; S I I; Usmanghani K; Naveed S
    Pak J Pharm Sci; 2016 Jul; 29(4 Suppl):1443-9. PubMed ID: 27592478
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Treatment guidelines for hyperglycaemia in type 2 diabetes patients with stable chronic heart failure or ischemic cardiomyopathy without heart failure].
    Alonso-García A; García-Soidán FJ; Lisbona-Gil A
    Med Clin (Barc); 2010 May; 134(13):596-9. PubMed ID: 20303545
    [No Abstract]   [Full Text] [Related]  

  • 40. United Kingdom prospective diabetes study: a different perspective.
    Kabadi UM
    Endocr Pract; 2002; 8(1):61-4. PubMed ID: 11939763
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.